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institutions and pharmaceutical and non-pharmaceutical indus-
try is a promising strategic approach to promote sustainable
clinical research capacity. The government vision is that
beyond national boundaries, resource sharing and involvement
of private players are key factors to mitigate the high burden
of disease, nationally and regionally.
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Background Human hookworm infection is a major public
health issue in tropical low and middle-income countries with
severe consequences. To date, improvement of water supply,
sanitation, and hygiene is the major contributor to disease
control, and additional control tools are needed. Here, we
assess a phase I trial of a new hookworm vaccine candidate
Na-APR-1 (M74)/Alhydrogel and Na-GST-1/Alhydrogel in
Gabonese school-age children.
Methods A double-blind, randomised, controlled, dose-esca-
lation phase I clinical trial that aims to evaluate safety, reac-
togenicity and immunogenicity of Na-APR-1 (M74)/
Alhydrogel co-administered with Na-GST-1/Alhydrogel hook-
worm vaccines in children aged 6 to 10 years living in
hookworm-endemic area of Lambaréné, compared to the
hepatitis B vaccine (ENGERIX-B). Children received three
doses of assigned vaccines, delivered intramuscularly (del-
toid) on Days 0, 56, and 112 or 180. Safety is measured
from Day 0 through Day 14 by the occurrence of solicited
injection site and systemic reactogenicity events. Clinical
laboratory evaluations were performed approximately 14
days after each immunisation. Unsolicited adverse events
were collected from Day 0 through approximately 1 month
after each vaccination.
Results A total of 135 children were screened, and 60, aged
6 to 10 years old, were randomised into 3 groups and
received 10 mg, 30 mg or 100 mg of Na-APR-1 (M74)/Alhy-
drogel and Na-GST-1 Alhydrogel, respectively, compared to
ENGERIX-B. At baseline, the mean age of the study popula-
tion was 7.4 years and the sex ratio 1.3 (male: female).
From Day 0 up to Day 14 after vaccination, the main soli-
cited adverse events were pain and swelling at injection sites
with 135 (26 of grade 2 and 1 of grade 3) and 9 events,
respectively. Regarding systemic adverse events, 3 occurrences
of grade 1 headache were recorded. Immunogenicity analyses
are underway.
Conclusion The preliminary results confirm that co-administra-
tion of the two hookworm vaccine candidates is safe and
well-tolerated in Gabonese children.
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Background In 2017, a North-South partnership was created,
to strengthen Bioethics Committees in African Lusophone Afri-
can countries (LAC), by joining the forces of National and
Institutional Research Ethics Committees (REC) and Univer-
sities in Angola, Cape Verde, Mozambique and Portugal. This
study is part of an EDCTP2-funded project and aims to
describe key RECs operating in LAC, its establishment dates
and further characteristics.
Methods Document analysis and interviews with REC repre-
sentatives of five LAC were conducted in April 2018. Legal
documents were obtained through official national sources.
Results We identified four National Ethics Committees, created
between 2000 and 2008 by ministerial or governmental
decree; only S. Tomé e Principe does not have an established
REC. In Angola, the National REC was created in 2000, and
since 2007, seven Institutional Committees were implemented
at faculty level. National REC in Cape Verde and Guinee-Bis-
sau (CNES) are unique and were founded in 2007 and 2009
respectively. In Mozambique, National REC (CNBS) dates to
2002, and since 2011, 8 Institutional Committees were
formed; they functioned as a network under the umbrella of
CNBS. Most National REC have representatives from health
professional associations, lawyers, civil society and religious
communities and have regular meetings (usually monthly). The
number of members ranges between 6 (CNES) and 13
(CNBS). In 2007, around 200 protocols were reviewed by
CNBS and 29 by CNES. Most of the National REC members
attended training activities in bioethics but at different levels.
Conclusion Few publications described REC operating in LAC;
this study fills this gap by reporting historical and functional
characteristics of RECs in five Lusophone African countries.
Additional tools based on quantitative and qualitative approaches
are being developed to assess more in-depth REC operational
characteristics and to identify their needs in order to target
training and capacity building initiatives underlying our project.
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Background The malaria blood stage vaccine candidate SE-36
is based on the serine repeat antigen of Plasmodium
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